Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus - Yahoo Finance
Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus - Yahoo Finance（摘要待生成）
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow (NASDAQ:IOVA) 2026-10-29 - Seeking Alpha
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer - Slideshow (NASDAQ:IOVA) 2026-10-29 Seeking Alpha
IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?
IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall? Stocktwits
Iovance Biotherapeutics (IOVA) Reports Promising Phase 2 Trial R - GuruFocus
Iovance Biotherapeutics (IOVA) Reports Promising Phase 2 Trial R GuruFocus
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results
Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results（摘要待生成）
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Iovance Biotherapeutics announced a conference call and live audio webcast for October 29, 2026, to present positive results from the IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous mNSCLC.
Iovance Biotherapeutics Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for mNSCLC
Iovance Biotherapeutics announced updated results from its Phase 2 IOV-LUN-202 trial for lifileucel in non-small cell lung cancer and introduced a new biomarker-enriched precision TIL strategy.
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
Iovance Biotherapeutics, Inc. announced it will host a conference call and live audio webcast on November 5, 2026, to discuss its third quarter 2026 financial results and provide corporate updates.
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026
Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026（摘要待生成）